CC
GBIO

Casdin Capital’s Generation Bio GBIO Stock Holding History

Casdin Capital’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-132,428
Closed -$9.72M – 45
2022
Q1 		$9.72M Hold
132,428
– – 0.44% 35
2021
Q4 		$9.38M Hold
132,428
– – 0.26% 46
2021
Q3 		$33.2M Sell
132,428
-28,693
-18% -$6.87M 0.83% 32
2021
Q2 		$43.3M Hold
161,121
– – 1.1% 26
2021
Q1 		$45.9M Hold
161,121
– – 1.37% 20
2020
Q4 		$45.7M Hold
161,121
– – 1.35% 17
2020
Q3 		$49.8M Hold
161,121
– – 2.23% 12
2020
Q2 		$33.8M Buy
+161,121
New +$35.9M 2% 17

Other funds holding GBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $291M AUM 19.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital's GBIO Position: Q2 2022 in Review

Casdin Capital sold out of Generation Bio (GBIO) in Q2 2022, closing a stake of 132,428 shares — an estimated $9.72M sold.

Casdin Capital first reported a position in GBIO in Q2 2020 and held it in 8 quarters. The position peaked at $49.8M in Q3 2020. 91 funds tracked by Wall St. Rank hold GBIO as of Q2 2022.

  • Casdin Capital reported no remaining Generation Bio position as of Q2 2022 after selling out during the quarter.
  • Casdin Capital sold 132,428 Generation Bio shares in Q2 2022, an estimated $9.72M.
  • Casdin Capital first reported a position in Generation Bio in Q2 2020 and held it in 8 quarters.
  • Casdin Capital's Generation Bio position peaked at $49.8M in Q3 2020.
  • 91 funds tracked by Wall St. Rank held Generation Bio as of Q2 2022.

Based on Casdin Capital's 13F filing for Q2 2022, filed 15 Aug 2022.